NCT06682611View on ClinicalTrials.gov

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

November 13, 2026

Study Completion Date

November 13, 2027

Conditions
Unresectable Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

SYHA1813

In accordance with the protocol

DRUG

SG001

In accordance with the protocol

DRUG

HB1801

In accordance with the protocol

DRUG

Carboplatin

In accordance with the protocol

DRUG

Cisplatin

In accordance with the protocol

DRUG

Paclitaxel

In accordance with the protocol

DRUG

Etoposide

In accordance with the protocol

DRUG

Everolimus

In accordance with the protocol

DRUG

Regorafenib

In accordance with the protocol

All Listed Sponsors
lead

Shanghai Runshi Pharmaceutical Technology Co., Ltd

INDUSTRY

NCT06682611 - Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Biotech Hunter | Biotech Hunter